Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q1 2021 · 10-Q
Revenue$1.27M$1.27M+12.0% vs Q1 2020 Net Income-$1.85M-$1.85MN/M vs Q1 2020 EPS Diluted-$0.06-$0.06N/M vs Q1 2020 Operating Income-$1,804,595N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
Margins · derivedOperating margin-142.2%+66.9 pt vs Q1 2020
Net margin-146.0%+38.0 pt vs Q1 2020
ended Mar 31, 2021 · filed May 12, 2021 · 42 d after period end